UK markets close in 5 hours 42 minutes

RedHill Biopharma Ltd. (RDHL)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.3556-0.0280 (-7.30%)
At close: 04:00PM EDT
0.3571 +0.00 (+0.42%)
After hours: 06:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3836
Open0.3790
Bid0.2590 x 200
Ask0.4485 x 200
Day's range0.3400 - 0.3800
52-week range0.2570 - 3.2800
Volume777,447
Avg. volume270,962
Market cap11.332M
Beta (5Y monthly)3.63
PE ratio (TTM)0.09
EPS (TTM)4.0000
Earnings date24 Jul 2024 - 28 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC (the "Agreement"). As a result of the Agreement, RedHill received approximately $9.9 million in cash and gained full control over an additional $0.74 million currently held in a restricted account, leading to an increase of approximately $12.2 million in

  • PR Newswire

    RedHill Biopharma Terminates License Agreement for Aemcolo®

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the mutual decision with Cosmo Technologies Ltd. ("Cosmo") to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea (the "License Agreement"). The License Agreement, initially dated October 17, 2019, will be officially terminated on October 8, 2024.

  • PR Newswire

    RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent notice of allowance for opaganib[4] in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response, providing protection for opaganib's potential use with a range of approved and in-development immune checkpoint inhibitors (ICIs) across a growing range of indications through 2040. The patent wi